Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The American Journal of Pathology|February 13, 2002
Versican is differentially expressed in human melanoma and may play a role in tumor developmentMalika Touab, Juan Villena, Carlos Barranco, et al.
Journal of Medical Case Reports|June 4, 2016
Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case reportDavid Casadevall, Joana Vidal, Fernando Gallardo, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|September 10, 2019
Prognostic value of stem cell markers in glioblastomaFrancesc Alameda, José María Velarde, Cristina Carrato, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 30, 2010
PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent eventsLaia Agell, Silvia Hernández, Marta Salido, et al.
Oxidative Medicine and Cellular Longevity|October 5, 2020
Amyloid Beta-Peptide Increases BACE1 Translation through the Phosphorylation of the Eukaryotic Initiation Factor-2<i>α</i>Pol Picón-Pagès, Daniela A Gutiérrez, Alejandro Barranco-Almohalla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2013
Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancerIsrael Cañadas, Federico Rojo, Álvaro Taus, et al.
Oncotarget|April 1, 2015
Cytoplasmic accumulation of NCoR in malignant melanoma: consequences of altered gene repression and prognostic significanceFernando Gallardo, Andreina Padrón, Ricard Garcia-Carbonell, et al.
Cells|March 29, 2023
Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive BiomarkerNeus Martínez-Bosch, Noelia Vilariño, Francesc Alameda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2020
Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from ImmunotherapyCristina Carrato, Francesc Alameda, Anna Esteve-Codina, et al.
Pageof 1